Screener
Nektar Therapeutics NKTR Preferred Stock Par Value Per Share
Preferred Stock Par Value Per Share at other companies
Other financials
Where this comes from
Reported directly by Nektar Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockParOrStatedValuePerShare.
The source filing: Nektar Therapeutics’s 10-Q, filed May 8, 2026.
- Filed
- May 7, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-212596
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 187,055 | 190,574 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares designated or outstanding at March 31, 2026 or December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value; 390,000,000 shares authorized; 29,472,092 shares and 20,378,832 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 3 | 2 |
| Capital in excess of par value | 4,382,437 | 3,850,099 |
| Accumulated other comprehensive income (loss) | (1,034) | 17 |
| Accumulated deficit | (3,805,190) | (3,760,286) |
Item 1. Condensed Consolidated Financial Statements—Unaudited:
FAQ
- What is Nektar Therapeutics's preferred stock par value per share?
- Nektar Therapeutics (NKTR) reported preferred stock par value per share of $0.00 in Q1 2026.
- How has Nektar Therapeutics's preferred stock par value per share changed year-over-year?
- Nektar Therapeutics's preferred stock par value per share decreased by 0.0% year-over-year, from $0.00 to $0.00.
- What is the long-term trend for Nektar Therapeutics's preferred stock par value per share?
- Over 5 years (2020 to 2025), Nektar Therapeutics's preferred stock par value per share has grown at a 0.0% compound annual growth rate (CAGR), from $0.00 to $0.00.
- What does preferred stock par value per share mean?
- The par value per share of preferred stock is a nominal value assigned to preferred shares for accounting and legal purposes. It does not reflect the market value or the liquidation preference of the stock. It is primarily a regulatory and historical accounting figure.
Ask your AI about Nektar Therapeutics's preferred stock par value per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude